Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2018
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Amphastar Pharmaceuticals (AMPH) PT Lowered to $22 at Needham & Company
August 9, 2018 1:38 PM EDTNeedham & Company lowered its price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $22.00 (from $24.00) while maintaining a Buy rating.
Analyst Serge Belanger remains positive as the recent approval of generic Isuprel, along with medroxyprogesterone and neostigmine will continue driving growth in... More
Amphastar Pharma (AMPH) Misses Q2 EPS by 4c
August 8, 2018 4:13 PM EDTAmphastar Pharma (NASDAQ: AMPH) reported Q2 EPS of $0.03, $0.04 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $71 million versus the consensus estimate of $62.9 million.
For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.
... More